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INTRODUCTION
Acromegaly is a serious, chronic endocrine disorder cha-
racterized by exaggerated growth hormone (GH) secretion
and increased levels of insulin-like growth factor-1 (IGF-1).
Treatment modalities include somatostatin analogues and
pegvisomant and/or radiotherapy following pituitary tumor
resection.
1 Pegvisomant is a pegylated analogue of human
GH and functions as a GH receptor antagonist. Pegvisomant
acts in the periphery and significantly decreases serum IGF-1
levels.
2 Various studies have shown that pegvisomant is safe
and well-tolerated and is an effective therapy for acromegaly
patients. Possible adverse effects of pegvisomant treatment
include self-limited erthematous injection-site reactions, mild
liver toxicity, influenza-like syndrome and headache.
3 Here,
we describe an acromegalic patient who developed lipohy-
pertrophy following initiation of pegvisomant therapy.
CASE REPORT
A 61-year-old female patient was diagnosed with acro-
megaly eight years ago. The diagnosis of acromegaly was
confirmed by elevated serum IGF-1 levels accompanied by
failure of GH suppression following a 75 g glucose load. The
patient displayed a 22x17x16 mm pituitary adenoma, which
was operated transsphenoidally two months after diagnosis.
After surgery, the patient was treated with long-acting
octreotide LAR for persistent symptoms. After 14 months of
octreotide therapy, 0.5 mg cabergoline administered 3 days
a week was added to the treatment regimen to address
unremitting symptoms. The patient underwent a gamma-
knife procedure three years after the initial surgery to treat
the residual disorder, which was identified by persistently
high levels of IGF-I and magnetic resonance imaging (MRI).
At the 4
th year of follow up, the patient displayed an IGF-I
level of 485 ng/ml. At this point (December 2009), carbego-
line treatment was discontinued and the patient was given
subcutaneous injections of 10 mg pegvisomant per day. The
patient was advised to alternate the injection areas around
the arms, thighs and the abdominal wall. After two months
of treatment, the patient found soft, painful swellings on her
arms, thighs and the abdominal wall. Clinical examination
found a clearly visible thickening of the tissues in these
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Figure 1 - Areas of lipohypertrophy on the anterior abdominal
wall.
Figure 2 - Sagittal T1 weighted MRI of the left arm shows
lipomatous hypertrophy (arrows) at the injection site. Note the
normal subcutaneous fat (asterisks) where injections were
performed.
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931areas (Figure 1). No significant increase was detected in
serum IGF-1 levels, indicating that the treatment was
effective. Ultrasonography revealed a subcutaneous fat
hypertrophy in the extremities. MRI of the left arm
confirmed lipomatous hypertrophy at the injection site
(Figure 2).
The accuracy of the injection sites and the drug applica-
tions were controlled by a dedicated nurse (Somavert
education service). The patient was dissatisfied with the
lipohypertrophy at the sites of injection, and pegvisomant
therapy was therefore discontinued.
DISCUSSION
Somatostatin analogues and pegvisomant are frequently
used in the treatment of acromegaly. Pegvisomant is a pegy-
lated analogue of human GH that blocks hepatic production
of IGF-1. The adverse effects of pegvisomant therapy include
self-limited erythematous injection-site reactions, mild liver
toxicity, influenza-like syndrome, headache, asthenia, diar-
rhea, arthralgia and hypercholesterolemia.
3
Lipodystrophy is a disease of the adipose tissue. It can be
localized and acquired by administration of particular
drugs. If the adipose changes are related to depressed areas
of skin, the disease is called lipoatrophy. Lipohypertrophy
is an enlargement of fat tissue caused by subcutaneous
deposition of adipose and is associated with parenteral drug
administration. The pathogenesis of lipohypertrophy is
unclear. It is known that growth hormone and IGF-1 both
display lipolytic activity. Blockage of growth hormone
action through pegvisomant therapy can affect adipose size
and increase local adiposity.
4-7 Immunologic factors can also
contribute to lipodystrophy. An inflammatory reaction to
substitutions of pegvisomant can often cause this disorder.
8
However, a biopsy of a pegvisomant-induced lipohyper-
trophy from an acromegalic patient showed normal-
appearing mature adipocytes with no fat necrosis and no
inflammatory cells. Additionally, the biopsy showed no
anti-pegvisomant antibodies.
7
To our knowledge, the literature contains 4 reports
describing 11 patients who developed lipodystrophy during
pegvisomant therapy
5-8 (Table 1). These reports describe
lipohypertrophy in 10 patients and lipoatrophy in 1 patient.
Maffei et al. have reported one male and one female patient
who suffered from lipohypertrophy on the abdominal wall,
confirmed by ultrasonography and MRI, following 1 month
of pegvisomant therapy. These patients were advised to
avoid abdominal injections and alternate the injection sites.
5
Salvatore et al. reported pegvisomant-induced lipoatrophy.
6
Marazuela et al. described lipohypertrophy on the left
arm of a female patient caused by pegvisomant therapy.
Thislipohypertrophyresolvedonceinjectionsatthesamesite
were ceased.
7 Bonert et al. identified seven different cases of
lipohypertrophy induced bypegvisomanttherapy;twoofthe
patients began rotating the injection site, and four patients
discontinued pegvisomant therapy.
8
It is worth noting that 9 of the 11 patients described in the
literature were female. Thus, pegvisomant-induced lipohy-
pertrophy can be referred to as a gender-specific response.
In most cases, lipohypertrophy was reversed after the
injection site was rotated or treatment was discontinued. It
is unknown whether the development of lipohypertrophy is
associated with the dose or frequency of injection.
5,7,8 In our
patient, pegvisomant therapy was administered together
with a low dose of octreotide LAR. The treatment effectively
normalized IGF-1 levels, but pegvisomant treatment was
stopped due to discomfort caused by lipohypertrophy.
In conclusion, pegvisomant injection appears to have
induced lipohypertrophy in our patient following two
months of therapy. We recommend injection site rotation
to different parts of the body, which should prevent the
development of lipohypertrophy. Physicians should be
aware of this complication and carefully monitor patients
under pegvisomant treatment.
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